NATCOPHARM

March 24 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - TO INCORPORATE WHOLLY OWNED SUBSIDIARY IN NIGERIA WITH INVESTMENT UP TO $100,000

• NATCO PHARMA - TO LIQUIDATE WHOLLY OWNED SUBSIDIARY IN AUSTRALIA

• NATCO PHARMA - BOARD APPROVES SCHEME OF ARRANGEMENT WITH NATCO CROP HEALTH SCIENCES

• NATCO PHARMA - CROP HEALTH SCIENCES TO ISSUE 1:1 SHARES TO NATCO PHARMA SHAREHOLDERS

Source text: ID:nNSE41gmTn

Further company coverage: NATP.NS

((Reuters.Briefs@thomsonreuters.com;))

** Analysts highlight strong semaglutide opportunity as ~10 Indian firms roll out generics

** Novo Nordisk's semaglutide patent expires this week

** Nomura says Zydus Lifesciences ZYDU.NS, Alkem Laboratories ALKE.NS, Sun Pharmaceutical Industries SUN.NS among most differentiated launches

** Adds Zydus's adjustable-dose reusable pen key differentiator

** Note Alkem "aggressive on pricing", with disposable pens at 2,000 rupees/month vs peers at 4,200-5,200 rupees

** Sees India's semaglutide market exceeding 120 bln rupees ($1.28 bln) in five years; India's obesity drug market at ~15 bln rupees as of March, per Pharmarack estimates

** Macquarie says Torrent Pharmaceuticals TORP.NS gains first-mover advantage in oral semaglutide

** Flags steep discounts of 50%-80% on pens, up to 85% on vials from Eris Lifesciences ERIS.NS, Glenmark Pharmaceuticals GLEN.NS, Natco Pharma NATP.NS

** Sees near-term price erosion before volume-driven expansion

($1 = 93.9125 Indian rupees)

(Reporting by Yagnoseni Das in Bengaluru)

((Yagnoseni.Das@thomsonreuters.com;))

March 20 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - LAUNCHES SEMAGLUTIDE GENERIC INJECTION MULTI DOSE VIALS IN INDIA

• NATCO PHARMA - MULTI DOSE VIALS LAUNCHED AT 1,290 RUPEES AND 1,750 RUPEES PER MONTH

• NATCO PHARMA - PEN DEVICE PRICED AT 4,000 RUPEES AND 4500 RUPEES PER MONTH, LAUNCH EXPECTED APRIL 2026

Source text: ID:nNSE2S1pW8

Further company coverage: NATP.NS

((Reuters.Briefs@thomsonreuters.com;))

March 18 (Reuters) - Natco Pharma Ltd NATP.NS:

• BOARD TO CONSIDER DEMERGER OF AGROCHEMICALS DIVISION

Source text: ID:nBSEtvJ4y

Further company coverage: NATP.NS

((Reuters.Briefs@thomsonreuters.com;))

March 3 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - LAUNCHES POMALIDOMIDE CAPSULES IN U.S. MARKET

Source text: ID:nNSEHZsrg

Further company coverage: NATP.NS

((Reuters.Briefs@thomsonreuters.com;))

March 3 (Reuters) - Breckenridge Pharmaceutical:

• BRECKENRIDGE PHARMACEUTICAL- BRECKENRIDGE LAUNCHES POMALIDOMIDE CAPSULES

• BRECKENRIDGE PHARMACEUTICAL-POMALIDOMIDE CAPSULES AVAILABLE ONLY THROUGH PS-POMALIDOMIDE REMS PROGRAM

Source text: ID:nPn4Q6sTZa

((Reuters.Briefs@thomsonreuters.com;))

Feb 25 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - COMPANY TO LAUNCH SEMAGLUTIDE IN INDIA IN MARCH 2026

Source text: ID:nBSE4rCg7D

Further company coverage: NATP.NS

((Reuters.Briefs@thomsonreuters.com;))

Feb 24 (Reuters) - Eris Lifesciences Ltd ERIS.NS:

• ANNOUNCES STRATEGIC PARTNERSHIP WITH NATCO PHARMA FOR SEMAGLUTIDE LAUNCH IN INDIA

Further company coverage: ERIS.NS

((Reuters.Briefs@thomsonreuters.com;;))

** Natco Pharma NATP.NS jumps ~11% to 913 rupees

** Pharma co gets Indian drug regulator's approval to manufacture and market generic semaglutide injection in country; injection used to treat type-2 diabetes mellitus, manage weight

** Product launch likely in March

** Trading volume at more than 8x the 30-day average

** YTD, NATP up ~1% vs ~2% fall in Nifty 500 index .NIFTY500

(Reporting by Vijay Malkar)

((VijayDattaram.Malkar@thomsonreuters.com;))

Feb 13 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - API UNIT IN CHENNAI RECEIVES ESTABLISHMENT INSPECTION REPORT FROM U.S. FDA

• NATCO PHARMA - API UNIT IN CHENNAI RECEIVES EIR FROM U.S. FDA

• NATCO PHARMA - COMPANY RECEIVED SEVEN OBSERVATIONS

• NATCO PHARMA - RECEIVED EIR CLASSIFIED AS VOLUNTARY ACTION INDICATED

Source text: ID:nBSEM8T3j

Further company coverage: NATP.NS

((Reuters.Briefs@thomsonreuters.com;))

Feb 12 (Reuters) - Natco Pharma Ltd NATP.NS:

• DEC-QUARTER CONSOL NET PROFIT 1.52 BILLION RUPEES

• DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 6.47 BILLION RUPEES

• RE-APPOINTMENT OF RAJEEV NANNAPANENI AS CEO

• DECLARED DIVIDEND OF RS. 1.50 RUPEES PER SHARE

• RE-APPOINTMENT OF VENKAIAH CHOWDARY NANNAPANENI AS CHAIRMAN & MANAGING DIRECTOR

Further company coverage: NATP.NS

((Reuters.Briefs@thomsonreuters.com;))

Feb 3 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - RECEIVES TENTATIVE APPROVAL FOR ERDAFITINIB TABLETS

Source text: ID:nBSE19q71R

Further company coverage: NATP.NS

((Reuters.Briefs@thomsonreuters.com;;))

Jan 30 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - NATCO PHARMA ASIA BUYS 49% OF PT NATCO LOTUS FARMA FROM PT LOTUS FARMA INDONESIA

• NATCO PHARMA - COST OF ACQUISITION IS ABOUT 77 MILLION RUPEES

Source text: ID:nNSEW2yQ3

Further company coverage: NATP.NS

((Reuters.Briefs@thomsonreuters.com;))

** Natco Pharma NATP.NS rises 3.3% to 840 rupees

** Delhi Court dismisses appeal filed against co by F. Hoffmann-La Roche AG over launch of Risdiplam drug in India

** Judgment paves way for co to launch generic version of drug 'Risdiplam', used to treat spinal muscular atrophy

** Co to launch product with immediate effect at 15,900 rupees; offer some discount to certain deserving patients through its patient access programme

** Around 2.2 mln shares traded, more than 5x the 30-day avg

** YTD, NATP falls ~39%

(Reporting by Vijay Malkar)

((VijayDattaram.Malkar@thomsonreuters.com;))

Rewrites, updates shares, adds analysts' comments

By Ananta Agarwal and Rishika Sadam

Sept 26 (Reuters) - Indian pharmaceutical stocks .NIPHARM fell 2% on Friday after U.S. President Donald Trump announced a 100% tariff on imports of branded and patented drugs, effective Oct. 1.

The U.S. is India's largest market for pharmaceutical exports, accounting for over a third of the total volume, mostly of cheaper generic drugs.

Of the 20 index constituents, 18 traded in the red as of 2:37 p.m. IST.

Analysts described the decline as "sentimental", noting that India's exports to the U.S. are primarily generic medicines, which may not be affected by the tariffs.

Sun Pharmaceutical Industries SUN.NS, India's largest drugmaker by revenue and the heaviest stock on the index, fell about 3%. Sun Pharma markets patented drugs, including Ilumya, a psoriasis treatment approved by the U.S. FDA.

The company also has a contract manufacturing unit through EU partners for specialty drugs, where a 15% tariff applies to EU exports to the U.S., according to Vishal Manchanda, equity analyst at Systematix Group.

"The impact on Sun is not very meaningful," he said. "It may be between 1% to 3% of EBITDA."

Laurus Labs LAUL.NS declined the most among constituents of the index, down about 6%.

"There is a general worry that CDMO (contract drug manufacturing organisations) might be impacted as the U.S. moves manufacturing in-house," Manchanda added.

Biocon, which makes complex biosimilars for cancer treatment and has significant U.S. exposure, is down about 4.6%.

"Uncertainty remains whether complex generics and biosimilars will face future tariffs," ICICI Securities analyst Pankaj Pandey said in a note on Friday.

(Reporting by Ananta Agarwal in Bengaluru; Editing by Nivedita Bhattacharjee and Janane Venkatraman)

((Ananta.agarwal@thomsonreuters.com;))

Sept 18 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA LTD - FDA CONDUCTED INSPECTION AT NATCO PHARMA IN KOTHUR, HYDERABAD

• NATCO PHARMA LTD - RECEIVES EIR CLASSIFYING FACILITY AS 'VAI'

Source text: ID:nBSE8nbfJZ

Further company coverage: NATP.NS

((reuters.briefs@thomsonreuters.com;))

** Shares of Natco Pharma NATP.NS down 0.7% at 903 rupees, while Nifty Pharma index up 1.2%

** Earlier was at 871 rupees, its lowest level since June 27

** Co reported 28.1% y/y fall in Q1 consol net profit as expenses rose

** Co says business faced pricing pressure in U.S. product portfolio, incurred increased R&D expenses on account of high value projects

** Average rating by 8 analysts is "hold"; median PT is 1,040.5 rupees - data compiled by LSEG

** YTD, NATP down 35.1% vs 6.7% fall in Nifty Pharma index

($1 = 87.6138 Indian rupees)

(Reporting by Meenakshi Maidas in Bengaluru)

((meenakshi.maidas@thomsonreuters.com;))

July 23 (Reuters) - Adcock Ingram Holdings Ltd AIPJ.J:

• JSE: AIP - JOINT FIRM INTENTION ANNOUNCEMENT: OFFER BY NATCO PHARMA, DELISTING OF ADCOCK INGRAM AND WITHDRAWAL OF CAUTIONARY

• ADCOCK INGRAM HOLDINGS LTD - NATCO PHARMA TO BUY ALL ELIGIBLE SHARES OF ADCOCK INGRAM

• ADCOCK INGRAM HOLDINGS LTD - CASH CONSIDERATION OF ZAR75.00 PER SHARE FOR ADCOCK INGRAM

• ADCOCK INGRAM HOLDINGS LTD - CO'S ORDINARY SHARES TO BE DELISTED FROM JSE MAIN BOARD

Source text: ID:nJseW0054a

Further company coverage: AIPJ.J

((Reuters.Briefs@thomsonreuters.com;))

** Shares of Natco Pharma NATP.NS down nearly 2% to 897 rupees

** Drugmaker says U.S. FDA inspected its Hyderabad facility and noted "one observation"

** Co did not elaborate on the observation, but said it was "procedural" and that it was confident it could address it comprehensively

** Stock, on avg, rated "hold" with median PT 935.50 rupees - data compiled by LSEG

** YTD stock down 36%

(Reporting by Hritam Mukherjee in Bengaluru)

((Hritam.Mukherjee@thomsonreuters.com;))

** Shares of Natco Pharma NATP.NS rise 2.3% to 881.95 rupees

** Pharmaceuticals co's Q4 consol net profit rises 5.3% Y/Y to 4.07 bln rupees ($47.6 mln)

** Q4 revenue jumps 14.3% Y/Y, while expenses rose 23.5%

** Trading vols at 1.5 mln shares, 1.3x the 30-day average

** NATP down ~36% YTD

($1 = 85.4500 Indian rupees)

(Reporting by Vijay Malkar)

((VijayDattaram.Malkar@thomsonreuters.com;))

April 8 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA LTD - DELHI HIGH COURT DENIES ROCHE'S INJUNCTION PLEA AGAINST NATCO

• NATCO PHARMA LTD - UPDATES ON LEGAL PROCEEDINGS FOR RISDIPLAM LAUNCH IN INDIA

• NATCO PHARMA LTD - ROCHE APPEALS DECISION, APPELLATE BENCH DIRECTS STATUS QUO

• NATCO PHARMA LTD - PRICES RISDIPLAM AT 15,900 RUPEES MRP

• NATCO PHARMA LTD - TO OFFER DISCOUNT ON RISDIPLAM THROUGH PATIENT ACCESS PROGRAMME

• NATCO PHARMA: INTENDS TO LAUNCH RISDIPLAM AFTER CLARITY FROM APPELLATE BENCH, WHICH IS EXPECTED SHORTLY

Source text: ID:nBSE1wdNMH

Further company coverage: NATP.NS

((reuters.briefs@thomsonreuters.com;))

March 20 (Reuters) - Eli Lilly LLY.N on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 billion in global sales since its initial U.S. launch in 2022.

India, the world's most populous country, has high obesity rates and the second-highest number of people with type 2 diabetes. Around 11% of Indian adults are expected to become obese by 2035, according to the World Obesity Federation Atlas.

Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug:

NOVO NORDISK

The Danish drugmaker NOVOb.CO had said it aims to launch its blockbuster weight-loss drug, Wegovy, in India by 2026.

The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India.

Wegovy and Lilly's Mounjaro belong to the same class of treatments called GLP-1 agonists, which soared into popularity globally triggering a shortage of supply. GLP-1 drugs mimic a gut hormone that helps control blood sugar levels and slow digestion, making people feel fuller for longer.

SUN PHARMA

Sun Pharmaceutical SUN.NS, India's largest drugmaker by revenue, is developing its own GLP-1 treatment, utreglutide, for weight loss and type 2 diabetes.

The drugmaker said earlier this month it expects to launch the drug in the next four to five years.

BIOCON

Indian drugmaker Biocon BION.NS is developing its own version of Novo's Wegovy, as the drug is set to lose exclusivity next year in emerging markets such as India, Brazil, Mexico, and Saudi Arabia.

ZYDUS LIFESCIENCES

India's Zydus Lifesciences ZYDU.NS is developing the generic version of Semaglutide and plans on launching the drug after its patent expires in India.

CIPLA

Cipla CIPL.NS, India's third-largest drugmaker by sales, is among the Indian drugmakers making cheaper versions of Novo's Wegovy.

Cipla has also said it is open to partnering with Lilly to market Mounjaro in India.

DR. REDDY'S

India's Dr. Reddy's REDY.NS has said it plans to launch generic versions of Semaglutide in all the markets as Novo's patent expires.

LUPIN

India's Lupin LUPN.NS is another generic drugmaker looking to grab a share of the burgeoning obesity treatment market with its own version of Novo's Wegovy.

NATCO, MANKIND PHARMA, AUROBINDO PHARMA

Media reports say India's Natco Pharma NATP.NS, Mankind Pharma MNKI.NS, Aurobindo Pharma ARBN.NS are also developing cheaper versions of Novo's Wegovy.

Reuters was not able to independently verify the reports.

(Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)

((Mariam.ESunny@thomsonreuters.com;))

** Shares of India's Natco Pharma NATP.NS drop 16.5% to 1017 rupees, marking their biggest intraday loss since debut

** The drugmaker's Q3 consol net profit fell 37.5% y/y, while rev dropped 37.4% y/y

** Stock sees steepest fall since June 5, 2024, set for fifth straight session of losses, if current trend holds

** NATP stock has lost ~27% so far in 2025

(Reporting by Yagnoseni Das in Bengaluru)

((Yagnoseni.Das@thomsonreuters.com;))

Feb 12 (Reuters) - Natco Pharma Ltd NATP.NS:

• DIVIDEND 1.5 RUPEES PER SHARE

• DEC-QUARTER CONSOL NET PROFIT 1.33 BILLION RUPEES

• DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 4.75 BILLION RUPEES

Source text: [ID:]

Further company coverage: NATP.NS

((Reuters.Briefs@thomsonreuters.com;;))

Feb 10 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN LTD - CO AND NATCO RECEIVE U.S. FDA APPROVAL FOR BOSENTAN TABLETS

Source text: ID:nBSEb28kSJ

Further company coverage: LUPN.NS

((Reuters.Briefs@thomsonreuters.com;;))

Jan 30 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - ANNOUNCES APPROVAL OF ANDA FOR EVEROLIMUS TABLETS

• NATCO PHARMA - BRECKENRIDGE PHARMACEUTICAL TO LAUNCH PRODUCT IMMEDIATELY IN US

Source text: ID:nBSESdMF

Further company coverage: NATP.NS

((Reuters.Briefs@thomsonreuters.com;;))

Jan 8 (Reuters) - Natco Pharma Ltd NATP.NS:

• GETS TAX PENALTY DEMAND ORDER OF 3.8 MILLION RUPEES

Source text: ID:nNSE6CRw55

Further company coverage: NATP.NS

((Reuters.Briefs@thomsonreuters.com;;))

Nov 27 (Reuters) - Natco Pharma Ltd NATP.NS:

• SELLS LAND FOR 1.16 BILLION RUPEES

Source text: ID:nBSE3654XR

Further company coverage: NATP.NS

((Reuters.Briefs@thomsonreuters.com;))

Nov 21 (Reuters) - Natco Pharma Ltd NATP.NS:

• SUBMITS ANDA FOR RISDIPLAM FOR ORAL SOLUTION

• SUBMITTED ANDA WITH US FDA FOR GENERIC VERSION OF EVRYSDI (RISDIPLAM)

• EXPECTS TO BE ELIGIBLE FOR 180 DAYS OF SHARED MARKETING EXCLUSIVITY

Source text: ID:nBSE3BWpw7

Further company coverage: NATP.NS

((Reuters.Briefs@thomsonreuters.com;;))

Nov 20 (Reuters) - Natco Pharma Ltd NATP.NS:

• SOLD INVESTMENT HELD IN ISCA, INC FOR $2.1 MILLION

Source text: ID:nBSE9X7x6J

Further company coverage: NATP.NS

((Reutersbriefs@thomsonreuters.com;))